BRIVASIGN 50 Tablet is a specialized antiepileptic formulation designed for the effective management of partial-onset seizures associated with epilepsy. The active ingredient, Brivaracetam, belongs to a class of novel anticonvulsants known for their action on the synaptic vesicle protein 2A (SV2A), a protein critical to neuronal excitability and neurotransmitter release in the central nervous system. With a dose strength of 50 mg per tablet, BRIVASIGN 50 is indicated as adjunctive therapy in patients aged 16 years and older with epilepsy who are experiencing focal seizures, with or without secondary generalization.

Epilepsy is a chronic neurological disorder that affects millions of people worldwide, characterized by unpredictable seizures that can significantly impair quality of life. Among various forms of epilepsy, partial-onset (focal) seizures are the most common. These seizures originate in one area of the brain and may remain localized or spread to other regions. In many patients, achieving seizure control requires a combination of antiepileptic drugs (AEDs) that work through different mechanisms. BRIVASIGN 50 is a critical advancement in this context, offering potent anticonvulsant activity with a clean side effect profile.

Brivaracetam, the active molecule in BRIVASIGN 50, is structurally related to levetiracetam but has a 20-fold higher binding affinity to the SV2A protein, making it significantly more potent in modulating synaptic neurotransmission. Unlike sodium channel blockers or GABA analogues, Brivaracetam directly targets presynaptic vesicle release without affecting other receptors, reducing the likelihood of sedative and cognitive side effects. This selectivity results in enhanced seizure suppression with better tolerability, making BRIVASIGN 50 a preferred choice among neurologists for patients who cannot tolerate older AEDs or need improved seizure control.

The pharmacokinetics of BRIVASIGN 50 indicate rapid absorption, with peak plasma levels achieved within 1 hour of oral administration. Brivaracetam exhibits linear pharmacokinetics, allowing for predictable dosing. The bioavailability of the oral tablet is nearly 100%, and the compound is minimally bound to plasma proteins, allowing for efficient distribution. It undergoes metabolism primarily via hydrolysis and secondarily via CYP2C19-mediated hydroxylation, resulting in inactive metabolites. The half-life of Brivaracetam is approximately 9 hours, permitting twice-daily dosing, although once-daily regimens may also be considered in some cases. The drug is primarily excreted in the urine as metabolites, with no significant renal or hepatic accumulation in most patients.